PE20221168A1 - Agonistas del receptor npy2 - Google Patents

Agonistas del receptor npy2

Info

Publication number
PE20221168A1
PE20221168A1 PE2022000757A PE2022000757A PE20221168A1 PE 20221168 A1 PE20221168 A1 PE 20221168A1 PE 2022000757 A PE2022000757 A PE 2022000757A PE 2022000757 A PE2022000757 A PE 2022000757A PE 20221168 A1 PE20221168 A1 PE 20221168A1
Authority
PE
Peru
Prior art keywords
analogs
obesity
prevention
pyy
receptor agonists
Prior art date
Application number
PE2022000757A
Other languages
English (en)
Inventor
Peter Wilhelm Haebel
Albert Brennauer
Charlotte Stahl Madsen
Søren Ljungberg Pedersen
Stefan Peters
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20221168A1 publication Critical patent/PE20221168A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y

Abstract

Esta referido a analogos de PYY que tienen alanina en la posicion 4, lisina en la posicion 7, QRY como el extremo del terminal C y un grupo de prolongacion de semivida. Los analogos de la invencion son solubles a alrededor de pH 6 y 7. La invencion tambien se refiere a composiciones farmaceuticas que comprenden tales analogos de PYY y al uso medico de los analogos. Estos compuestos se emplean en el tratamiento y/o la prevencion de una variedad de enfermedades, tales como el tratamiento y/o la prevencion de la ingesta excesiva de alimentos, exceso de peso corporal, obesidad, enfermedades metabolicas y otras afecciones o trastornos relacionados con el exceso de peso corporal o la obesidad, por ejemplo, diabetes y enfermedades cardiovasculares.
PE2022000757A 2019-11-11 2020-11-09 Agonistas del receptor npy2 PE20221168A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19208394 2019-11-11
PCT/EP2020/081513 WO2021094259A1 (en) 2019-11-11 2020-11-09 Npy2 receptor agonists

Publications (1)

Publication Number Publication Date
PE20221168A1 true PE20221168A1 (es) 2022-07-25

Family

ID=68531488

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000757A PE20221168A1 (es) 2019-11-11 2020-11-09 Agonistas del receptor npy2

Country Status (18)

Country Link
US (2) US20210139548A1 (es)
EP (1) EP4058047A1 (es)
JP (1) JP2023500895A (es)
KR (1) KR20220100925A (es)
CN (1) CN114641303A (es)
AR (1) AR120440A1 (es)
AU (1) AU2020384729A1 (es)
CA (1) CA3156452A1 (es)
CL (1) CL2022001227A1 (es)
CO (1) CO2022006046A2 (es)
CR (1) CR20220206A (es)
EC (1) ECSP22037660A (es)
IL (1) IL292601A (es)
JO (1) JOP20220110A1 (es)
MX (1) MX2022005661A (es)
PE (1) PE20221168A1 (es)
TW (1) TW202134263A (es)
WO (1) WO2021094259A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230045088A (ko) * 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
AU2005316524B2 (en) 2004-12-13 2012-01-12 Amylin Pharmaceuticals, Llc Pancreatic Polypeptide Family motifs, polypeptides and methods comprising the same
EA017849B1 (ru) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соагонисты глюкагоновых/glp-1-рецепторов
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
AU2007360979B2 (en) 2007-11-14 2014-04-10 Amylin Pharmaceuticals, Llc Methods for treating obesity and obesity related diseases and disorders
CA2747109A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
EA020497B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
PL2370462T3 (pl) 2008-12-15 2015-01-30 Zealand Pharma As Analogi glukagonu
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
US20130096055A1 (en) 2009-11-13 2013-04-18 Novo Nordisk A/S Long-acting y2 receptor agonists
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CA2802897A1 (en) 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
WO2012168431A2 (en) 2011-06-10 2012-12-13 Novo Nordisk A/S Polypeptides
EP2793931A2 (en) 2011-12-23 2014-10-29 Zealand Pharma A/S Glucagon analogues
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US20160108098A1 (en) 2013-05-02 2016-04-21 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
SG11201602965WA (en) 2013-10-17 2016-05-30 Zealand Pharma As Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
PL3068796T3 (pl) 2013-11-14 2018-07-31 Keybioscience Ag Mimetyki kalcytoniny do leczenia chorób i zaburzeń
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
AU2016232218B2 (en) 2015-03-18 2020-09-10 Boehringer Ingelheim International Gmbh Amylin analogues
WO2016166289A1 (en) 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
TWI749381B (zh) 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法

Also Published As

Publication number Publication date
IL292601A (en) 2022-07-01
JOP20220110A1 (ar) 2023-01-30
CL2022001227A1 (es) 2023-02-03
JP2023500895A (ja) 2023-01-11
EP4058047A1 (en) 2022-09-21
CR20220206A (es) 2022-06-16
WO2021094259A1 (en) 2021-05-20
ECSP22037660A (es) 2022-06-30
AR120440A1 (es) 2022-02-16
TW202134263A (zh) 2021-09-16
KR20220100925A (ko) 2022-07-18
AU2020384729A1 (en) 2022-04-14
CO2022006046A2 (es) 2022-05-20
US20210139548A1 (en) 2021-05-13
MX2022005661A (es) 2022-09-07
CN114641303A (zh) 2022-06-17
CA3156452A1 (en) 2021-05-20
US20230340039A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
PE20221168A1 (es) Agonistas del receptor npy2
CO2020014180A2 (es) Derivados de gip y usos de estos
AR100945A1 (es) Proteínas de fusión mic-1 y usos de las mismas
MX2020007410A (es) Formulaciones, composiciones y métodos farmacéuticos de péptido yy.
EP2496245A4 (en) ANALOG OF PITUTIC ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHOD OF USE THEREOF
BR112019011139A8 (pt) conjugados que compreendem um agonista dual de glp/glucagon, um ligante e ácido hilaurônico
PE20142332A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
RU2017146657A (ru) Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона
CL2023000357A1 (es) Agonistas del receptor npy2 solubles
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
EA201591338A1 (ru) Гастроретентивная лекарственная форма секвестранта желчных кислот с замедленным высвобождением для перорального применения
RU2017112982A (ru) Композиции иммуногенных/терапевтических гликоконъюгатов и их применения
AU2019363725B2 (en) Stable semaglutide compositions and uses thereof
JP2014522414A5 (es)
BR112019004210A2 (pt) composição farmacêutica, método e kit para tratamento da deficiência de hormônio do crescimento
UY38473A (es) Formulaciones farmacéuticas para una administración subcutánea
EA202191511A1 (ru) Составы на основе аналога пептида оксинтомодулина
AR072120A1 (es) Fenil-alquil-piperazinas que tienen actividad moduladora de tnf, un proceso de preparacion del compuesto, una composicion farmaceutica que lo contiene, un medicamento en base al compuesto y la utilizacion del compuesto para preparar un medicamento
EA202190923A1 (ru) Аналоги белка тирозин-тирозин и способы их применения
AR117097A1 (es) Formulaciones farmacéuticas para una administración subcutánea
BR112022006297A2 (pt) Agonistas de receptor de npy2
ZA202306305B (en) Pharmaceutical compounds
EA201991384A1 (ru) Комбинации диклофенака и антагонистов h2-рецептора для лечения боли и воспаления
AR120878A1 (es) Polipéptidos que comprenden mutantes del vegf-a humano con re-arreglos de puentes disulfuro y composiciones que los contienen